A 76-week Prospective, Open-label, Multicenter Study to Evaluate the Long-term Effect of Rivastigmine Capsule and Transdermal Patch on Worsening of the Underlying Motor Symptoms of PD in Patients With Mild to Moderately Severe Dementia Associated With Parkinson's Disease (PDD)

Trial Profile

A 76-week Prospective, Open-label, Multicenter Study to Evaluate the Long-term Effect of Rivastigmine Capsule and Transdermal Patch on Worsening of the Underlying Motor Symptoms of PD in Patients With Mild to Moderately Severe Dementia Associated With Parkinson's Disease (PDD)

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jan 2015

At a glance

  • Drugs Rivastigmine (Primary) ; Rivastigmine (Primary)
  • Indications Dementia; Parkinson's disease
  • Focus Adverse reactions; Registrational
  • Sponsors Novartis
  • Most Recent Events

    • 13 Sep 2011 Motor symptom results presented at the 15th Congress of the European Federation of Neurological Societies.
    • 09 Jun 2011 Results presented at the 15th International Congress of Parkinson's Disease and Movement Disorders.
    • 10 May 2011 Additional trial locations (Argentina and Australia) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top